Gulf Medical Co Ltd

gulfmedical.com

Gulf Medical Company was founded in 1983 as a medical supply company specialized in the sales and marketing of medical devices and equipment, with the sole proprietorship of the vision “To bring the most innovative state of the art medical technology and solutions to our market”. Today, after more than two decades, that vision, not only lives on but also continues to gain momentum. Thanks to our customers and suppliers who contributed with precision.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

news image

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More

Medical

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

news image

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More

Medical

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

news image

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More

Cell and Gene Therapy

RESEARCH DEMONSTRATES NOVEL HIT RECEPTOR ENHANCES T CELL ANTIGEN SENSITIVITY AND ELICITS SUPERIOR TUMOR CONTROL

Mnemo Therapeutics | January 24, 2022

news image

The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance recognition of tumors by engineered T cells, addressing an underlying cause for relapsed tumors in patients after chimeric antigen receptor therapy. The study demonstrates high antigen sensitivity of HLA-independent T-cell receptors, created by editing the TCR Alpha Constant chain locus in human peripheralbio blood Tcells. Low antigen expression<...

Read More
news image

FIRMENICH OPENS NEW BIOTECHNOLOGY AND NATURALS PILOT PLANT AND LABORATORY IN GENEVA

Firmenich | October 01, 2020

Firmenich, the world's largest privately-owned Perfume and Taste company, is proud to announce the opening of its new biotechnology and naturals pilot plant and laboratory in Geneva. Benefiting from the latest digital technology, the facility opens a new era for the development of ingredients and clean label solutions by providing faster speed-to-market and greater flexibility for customer collaboration. Integrated into the Group's flagship ingredients production site at La Plaine, Genev...

Read More
news image

Medical

TRIALSPARK, COMMITTS TO IMPROVE SPEED, QUALITY, AND INNOVATION OF CLINICAL TRIALS, ANNOUNCES COLLABORATION WITH ADITUM BIO

TrialSpark | December 21, 2020

TrialSpark, a tech-enabled drug development accomplice focused on improving the speed, quality, and innovation of clinical trials, officially announces a collaboration with Aditum Bio, a San Francisco-based venture endeavor firm engaged with respect to getting and creating biotechnology resources that will benefit patients. Anteris Bio in-licensed ANT-401 from vTv Therapeutics, to be studied in CKD and across multiple etiologies of renal diseases. As Aditum Bio's drug developm...

Read More
news image

Medical

NIKANG THERAPEUTICS COMPLETES $200 MILLION SERIES C FINANCING TO ADVANCE HIGHLY DIFFERENTIATED SMALL MOLECULES ADDRESSING DIFFICULT-TO-DRUG TARGETS

NiKang Therapeutics | May 31, 2021

NiKang Therapeutics Inc., a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to assist patients with unmet medical needs; today announced the completion of an oversubscribed $200 million Series C financing led by Cormorant Asset Management, HBM Healthcare Investments, and Octagon Capital Advisors with participation from a premier syndicate of funds, including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Grou...

Read More
news image

Cell and Gene Therapy

RESEARCH DEMONSTRATES NOVEL HIT RECEPTOR ENHANCES T CELL ANTIGEN SENSITIVITY AND ELICITS SUPERIOR TUMOR CONTROL

Mnemo Therapeutics | January 24, 2022

The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance recognition of tumors by engineered T cells, addressing an underlying cause for relapsed tumors in patients after chimeric antigen receptor therapy. The study demonstrates high antigen sensitivity of HLA-independent T-cell receptors, created by editing the TCR Alpha Constant chain locus in human peripheralbio blood Tcells. Low antigen expression<...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us